Cambridge, Mass., USA - January 7, 2015, Cambridge, Mass., USA - Codiak BioSciences appointed Ariel Jasie as chief business officer, Linda Bain as CFO and Konstantin Konstantinov as SVP, manufacturing and process sciences.
Article continues below
Mr. Jasie joined Codiak from Celgene Corporation, where he led the Strategy and Operations Group in the Research and Early Development franchise. He previously served on the Celgene Business Development team.
Mr. Jasie initially joined Celgene as Corporate Counsel, focusing on transactional work and supporting Business Development, Technical Operations, Research, and Clinical Operations.
Prior to Celgene, Mr. Jasie served as Commercial Counsel at Reliant Pharmaceuticals, which was acquired by GSK in 2007.
Mr. Jasie received his B.A. from the University of Maryland at College Park and his J.D. from Brooklyn Law School.
Ms. Bain joined Codiak from Avalanche Biotechnologies where she was chief financial officer. She previously served as vice president of finance, business operations and treasurer at bluebird bio.
Ms. Bain has held senior roles at Genzyme Corporation, including vice president of finance, global manufacturing and operations and vice president of finance of Genzyme Genetics, where she was a member of the team that divested the business unit to LabCorp.
Earlier in her career, she served in senior finance roles at Fidelity Investments and AstraZeneca Pharmaceuticals and as an auditor at Deloitte & Touche.
Ms. Bain received her B.S in Accounting and Business Administration and an Honors Degree in Accounting and Business Administration from the University of the Free State, South Africa. She is a Certified Public Accountant.
Before joining Codiak, Mr. Konstantinov was responsible for the late-stage bioprocess and technology development at Sanofi's Boston Hub.
Prior to Sanofi, Dr. Konstantinov worked for Bayer in Berkeley, Ca. for 14 years, advancing to the position of Head of Process Sciences. He has published 60 peer reviewed papers and has more than 15 patents and patent applications. ■